Lynavoy (linerixibat) FDA approval: first IBAT inhibitor for PBC pruritus

The FDA's approval of Lynavoy (linerixibat) on March 17, 2026, marks a pivotal development in the management of primary biliary cholangitis (PBC). As the first and only therapy specifically approved in the United States for the treatment of cholestatic pruritus (severe chronic itching) in adult patients with PBC, Lynavoy addresses a profound unmet clinical need.

Linerixibat, originally discovered and developed by GSK (GlaxoSmithKline), is an oral ileal bile acid transporter (IBAT) inhibitor. Shortly before the approval in March 2026, GSK and Alfasigma S.p.A. announced an exclusive licensing agreement under which Alfasigma acquired the global rights to develop, manufacture, and commercialize linerixibat. The transaction officially completed in April 2026, placing the commercial launch and patient-support programs under Alfasigma’s direction.

For P&T committees, specialty pharmacies, and market-access teams, Lynavoy introduces a new targeted mechanism into the hepatology benefit design. While the drug offers significant clinical efficacy in reducing debilitating itch, its safety profile—primarily characterized by high rates of diarrhea—and strict label warnings regarding advanced liver disease will shape commercial prior-authorization (PA) criteria.

---

Short answer: what access teams need to know

• Approval Date: March 17, 2026, as novel drug approval #6 of the year.
• Mechanism & Dosing: Oral small-molecule IBAT inhibitor that blocks the re-absorption of bile acids in the distal ileum. The recommended dose is 40 mg orally twice daily, swallowed whole at least 30 minutes before any food or beverage (other than water).
• Indication: Cholestatic pruritus in adult patients with primary biliary cholangitis (PBC).
• Clinical Efficacy (GLISTEN Phase 3): Achieved a statistically significant least-squares (LS) mean change in the Worst Itch Numerical Rating Scale (WI-NRS) of –2.86 from baseline in the linerixibat group compared to –2.15 in the placebo group (adjusted mean difference of –0.72; p = 0.001). Additionally, 56% of patients achieved a clinically meaningful ≥3-point reduction in WI-NRS compared to 43% on placebo.
• Safety Profile: Diarrhea was the most common adverse event, reported in 61% of linerixibat-treated patients versus 18% in the placebo group. The discontinuation rate due to diarrhea was approximately 4%.
• Usage Constraints & Warnings: Avoid use in patients with decompensated cirrhosis or a history of hepatic decompensation events (e.g., ascites, variceal hemorrhage, hepatic encephalopathy).
• Payer Gating: Payers are expected to require prior trial and failure of low-cost, off-label bile acid sequestrants (like cholestyramine) and strict confirmation of compensated liver function before approving coverage.

---

What is Lynavoy and why is it needed in PBC?

Primary biliary cholangitis (PBC) is a chronic, progressive autoimmune liver disease characterized by the destruction of intrahepatic bile ducts, leading to cholestasis (the accumulation of bile acids in the liver and blood). While therapies like ursodeoxycholic acid (UDCA) and obeticholic acid (Ocaliva) or peroxisome proliferator-activated receptor (PPAR) agonists focus on slowing disease progression and reducing alkaline phosphatase (ALP) levels, they do not consistently address the debilitating symptoms of the disease.

Among these symptoms, cholestatic pruritus is one of the most severe. It affects up to 70% of PBC patients at some point during their disease course. The itch associated with cholestasis is systemic, typically worse at night, and resistant to standard antipruritic therapies like antihistamines. It leads to severe sleep disruption, chronic fatigue, depression, and a dramatic decline in quality of life.

The Role of Bile Acids and the IBAT Mechanism

Pruritus in PBC is believed to be mediated by systemic pruritogens, primarily bile acids and lysophosphatidic acid (LPA), which accumulate in the blood and skin.

Linerixibat is an ileal bile acid transporter (IBAT) inhibitor. The IBAT protein (also known as the apical sodium-dependent bile acid transporter, or ASBT) is located on the luminal membrane of enterocytes in the distal ileum, where it is responsible for reabsorbing approximately 95% of bile acids from the intestinal lumen back into the portal circulation (enterohepatic circulation).

By selectively inhibiting IBAT, Lynavoy prevents the reabsorption of bile acids in the gut. This leads to:

1. Increased fecal excretion of bile acids.
2. A rapid and significant reduction in systemic bile acid concentrations in the blood.
3. A corresponding reduction in the accumulation of pruritogenic substances in the skin, alleviating the chronic itch response.

---

What did the Phase 3 GLISTEN trial show?

The FDA approval of Lynavoy was supported by data from the Phase 3 GLISTEN clinical trial (NCT04950127), a multi-center, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of oral linerixibat over 24 weeks in adults with PBC experiencing moderate-to-severe cholestatic pruritus.

Efficacy Results: Significant and Sustained Itch Reduction

The trial enrolled a highly symptomatic PBC population. The primary efficacy endpoint was the change from baseline to week 24 in the daily Worst Itch Numerical Rating Scale (WI-NRS), an 11-point scale where 0 represents "no itch" and 10 represents "worst itch imaginable."

• Primary Endpoint Achievement: The trial met its primary endpoint. The LS mean change in WI-NRS was –2.86 in the linerixibat group compared to –2.15 in the placebo group, yielding a statistically significant adjusted mean difference of –0.72 (95% CI –1.15 to –0.28; p = 0.001).
• Onset of Action: Efficacy was rapid, with statistically significant separation in itch reduction observed as early as week 2 of starting treatment, and the response was sustained throughout the 24-week dosing period.
• Clinically Meaningful Response: A key secondary endpoint evaluated the percentage of patients achieving a clinically meaningful improvement, defined as a ≥3-point reduction in the Worst Itch NRS. In the linerixibat arm, 56% of patients met this threshold compared to 43% in the placebo arm.
• Sleep and Quality of Life: Patients treated with linerixibat reported significant reductions in itch-related sleep interference and improvements in disease-specific quality of life scores, particularly in the social and emotional domains of the PBC-40 questionnaire.

Safety Analysis: Managing Gastrointestinal Adverse Events

The primary safety finding in the GLISTEN trial was a high rate of gastrointestinal adverse events, which is a class-wide effect of IBAT inhibitors due to the increased concentration of bile acids remaining in the colon.

• Incidence of Diarrhea: Diarrhea was reported in 61% of patients in the linerixibat group, compared to 18% in the placebo group.
• Severity: The majority of diarrhea cases were reported as mild-to-moderate in severity.
• Discontinuation Rate: Despite the high incidence, the rate of treatment discontinuation due to diarrhea was low, occurring in approximately 4% of patients in the linerixibat group (versus <1% in the placebo group). This indicates that the symptom was manageable for most patients in a clinical trial setting.
• Other Gastrointestinal Events: Abdominal pain was also among the most frequently reported adverse events (about 18% of linerixibat-treated patients).

Clinical Management of Diarrhea in Practice

To ensure patient persistence and avoid unnecessary drug discontinuation, clinical protocols suggest several proactive management steps for diarrhea:

1. Dietary Modification: Patients should be advised to reduce intake of dietary fats and simple sugars during the initiation phase.
2. Antidiarrheal Agents: Short courses of over-the-counter antidiarrheals, such as loperamide, may be utilized if symptoms are bothersome, under the guidance of the prescriber.
3. Titration and Timing: Taking the medication at a consistent time each day can help establish a predictable bowel pattern.

---

How does Lynavoy compare with other IBAT inhibitors?

While Lynavoy is the first IBAT inhibitor approved specifically for PBC-associated cholestatic pruritus in adults, the IBAT class is already represented in the market by two other agents: Bylvay (odevixibat) and Livmarli (maralixibat).

Understanding the differences between these agents is essential for formulary tiering and preventing off-label cross-utilization.

Key Takeaways from the Class Comparison

1. Indication Isolation: Lynavoy is specifically approved for adult PBC. Bylvay and Livmarli are approved for rare pediatric genetic disorders (Progressive Familial Intrahepatic Cholestasis [PFIC] and Alagille syndrome [ALGS]). Because Bylvay and Livmarli carry extremely high "ultra-orphan" pricing (frequently exceeding $300,000 annually), payers must ensure that Lynavoy is not used off-label for these pediatric indications, and vice versa.
2. Safety Profile: Both Lynavoy and Livmarli show high rates of diarrhea (~60%), whereas Bylvay shows lower rates (~10%). This is likely due to differences in systemic absorption and the specific enterocyte transporter binding kinetics of the molecules.
3. Dosing Convenience: Lynavoy is formulated as a simple oral tablet for adults, whereas the other two are designed as pediatric liquids or sprinkle capsules.

---

Comparison with Established Off-Label Therapies

Before the approval of Lynavoy, clinicians relied entirely on off-label medications to manage PBC-associated cholestatic pruritus. Payer P&T committees will evaluate Lynavoy's clinical utility against these low-cost options:

1. Bile Acid Sequestrants (e.g., Cholestyramine)

• Mechanism: Binds bile acids in the intestinal lumen, preventing absorption.
• Dosing: 4g packets taken 2 to 4 times daily, typically dissolved in water or juice.
• Limitations: Poor taste and texture lead to low patient adherence. More importantly, cholestyramine is non-selective and binds other medications (including UDCA, thyroid hormones, and oral contraceptives), requiring complex dosing schedules (spacing other drugs at least 1 hour before or 4 hours after cholestyramine).
• Cost: Extremely low (generic).

2. Rifampin

• Mechanism: Enhances hepatic metabolism and excretion of pruritogens by inducing the CYP3A4 pathway.
• Dosing: 150 mg to 300 mg orally twice daily.
• Limitations: Potential for severe drug-induced hepatotoxicity, requiring blood monitoring of liver enzymes every 2 weeks during initiation. Strong enzyme induction also leads to multiple drug interactions.
• Cost: Low (generic).

3. Opioid Antagonists (e.g., Naltrexone)

• Mechanism: Blocks central opioid receptors, which are believed to be overstimulated in cholestasis.
• Dosing: 50 mg orally once daily.
• Limitations: Can trigger acute, severe withdrawal-like reactions (pain, agitation, sweating) during the first few days of treatment.
• Cost: Low (generic).

---

What prior-authorization criteria will commercial payers require?

Given that Lynavoy represents a specialty drug for a symptomatic (rather than disease-modifying) indication, commercial payers will enforce structured prior-authorization (PA) gates to manage utilization.

Based on the clinical trial design and the FDA-approved label, payers are expected to structure their PA criteria around three main categories: diagnostic verification, safety screening, and step-therapy requirements.

1. Diagnostic Verification

• The patient must be an adult (18 years of age or older).
• Documented diagnosis of primary biliary cholangitis (PBC), confirmed by at least two of the following criteria:
  • Elevated alkaline phosphatase (ALP) levels.
  • Positive antimitochondrial antibody (AMA) titer.
  • Liver biopsy findings consistent with PBC.
• Documented moderate-to-severe cholestatic pruritus that has a significant impact on daily life (e.g., severe sleep disruption, skin excoriations from scratching).

2. Safety and Usage Gates (Liver Function Verification)

The FDA label advises against the use of Lynavoy in patients with advanced, decompensated liver disease. Payers will require:

• Documented baseline liver function tests (bilirubin, AST, ALT, albumin, and INR).
• Exclusion Criteria: Exclusion of patients with decompensated cirrhosis (Child-Pugh Class B or C) or a history of hepatic decompensation events (including ascites, variceal hemorrhage, or hepatic encephalopathy). The prescriber must verify that the patient has compensated liver disease (Child-Pugh Class A or no cirrhosis).

3. Step-Therapy (Prior Failure of Low-Cost Options)

Before approving a high-cost specialty drug like Lynavoy, payers will require a documented trial and failure of, or intolerance to, established first-line off-label therapies:

• Bile Acid Sequestrants: A documented trial of at least 4 weeks of cholestyramine (or colesevelam/colestipol). Cholestyramine is the current guideline-recommended first-line therapy for cholestatic pruritus, despite its poor tolerability and drug-binding issues.
• Other Off-Label Options: Some plans may also require a trial of other off-label oral options, such as rifampin (requires liver monitoring) or naltrexone, if bile acid sequestrants fail or are contraindicated.

4. Authorization and Reauthorization Timelines

• Initial Authorization: Granted for 6 months to allow the patient to demonstrate clinical response and verify tolerability (specifically that diarrhea does not lead to discontinuation).
• Reauthorization Criteria: Requires documentation from the prescriber showing a clinically meaningful reduction in itch severity (such as a ≥3-point reduction on the Worst Itch NRS or significant improvement in sleep) and the continued absence of hepatic decompensation.

---

Commercial Launch and the GSK-Alfasigma Transition

The commercial success of Lynavoy is heavily shaped by its recent ownership transition. In March 2026, GSK licensed the global commercialization rights to Alfasigma.

• Upfront and Milestone Payments: GSK received an upfront payment and is eligible for development and commercial milestone payments plus double-digit royalties.
• Launch Timeline: Alfasigma announced the completion of the transaction in April 2026 and is leading the U.S. commercial launch; at the time of approval, GSK and Alfasigma had not committed to a specific on-pharmacy date, and access teams should track Alfasigma's distribution announcements rather than assume an immediate wide launch.
• Specialty Distribution: Lynavoy will be distributed through a restricted network of specialty pharmacies to ensure close clinical monitoring of liver function and safety warnings.
• Patient Support Services: Alfasigma is launching a comprehensive patient-hub program to assist with prior-authorization navigation, co-pay cards for commercially insured patients, and nurse support services to help patients manage the high rate of diarrhea during the initiation phase.

---

Long-Term Market and Payer Implications

Hepatology access leads and PBM managers should consider the following long-term implications of Lynavoy's launch:

1. Quality-of-Life Metrics in Payer Evaluation

Historically, payers have prioritized disease-modifying therapies (such as those lowering ALP to prevent liver transplant) over symptomatic treatments. However, because cholestatic pruritus in PBC is so severe, payers are increasingly recognizing the "total cost of care" associated with untreated symptoms, including psychiatric referrals for depression and hospitalizations for skin infections secondary to excoriation. Lynavoy’s launch will test how PBMs evaluate "pure" quality-of-life drugs in the specialty hepatology space.

2. Monitoring the Child-Pugh Shift

Because PBC is a progressive disease, a patient who starts Lynavoy with compensated liver function (Child-Pugh A) may progress over time to decompensated cirrhosis (Child-Pugh B/C). P&T committees should implement annual review cycles that require re-evaluation of liver function tests and Child-Pugh scores to ensure the drug is discontinued if decompensation occurs, mitigating the risk of drug-induced liver injury.

Proactive Clinical Monitoring and Patient Compliance

Because Lynavoy is an oral medication that patients self-administer at home, clinical teams must establish clear guidelines for monitoring and compliance. While the drug does not require the intensive laboratory monitoring associated with some small-molecule therapies, the risk of progressive liver disease in PBC patients means that periodic evaluations are highly recommended. Specifically, hepatology practices should establish a baseline liver panel before starting treatment and re-evaluate patients at month 1, month 3, and every 6 months thereafter.

This monitoring schedule serves a dual purpose: first, it confirms that the patient’s liver function remains compensated (i.e., that they have not transitioned from Child-Pugh Class A to Class B or C, which would necessitate stopping the drug). Second, it provides clinical staff with an opportunity to check in on gastrointestinal tolerability, specifically managing any mild-to-moderate diarrhea. Proactive phone calls from specialty pharmacy nurses during the first two to four weeks of therapy have been shown to significantly reduce early discontinuation rates for IBAT inhibitors by reinforcing diet modifications and the appropriate use of rescue therapies like loperamide.

Furthermore, compliance tracking must be integrated into the specialty pharmacy refill authorization process. If a patient is not requesting refills on time, it may indicate that they are experiencing unmanaged gastrointestinal side effects and are taking the medication intermittently. This sub-therapeutic dosing can lead to a loss of efficacy and a return of severe pruritus. Specialty pharmacy case managers should conduct structured adherence calls every 30 days to assess side effects, reinforce correct administration timing (taking the tablet at the same time each day), and document clinical response. Payers will look for these documented compliance logs during the 6-month reauthorization review, and evidence of non-compliance or lack of therapeutic benefit will result in coverage termination.

---

FAQs

When was Lynavoy approved and by whom is it commercialized?

Lynavoy (linerixibat) was approved by the FDA on March 17, 2026. While discovered and developed by GSK, the exclusive global rights to commercialize and launch the drug were acquired by Alfasigma S.p.A. in a licensing agreement finalized in April 2026.

Can Lynavoy be used in patients with advanced liver disease or cirrhosis?

Lynavoy is indicated only for patients with compensated liver disease. The FDA-approved label advises that its use should be avoided in patients with decompensated cirrhosis or those with a history of hepatic decompensation (such as ascites, variceal hemorrhage, or hepatic encephalopathy), as these patients are at higher risk for adverse outcomes.

What is the most common side effect of Lynavoy?

The most common side effect is diarrhea, which was reported in 61% of patients treated with linerixibat in the Phase 3 GLISTEN trial (compared to 18% in the placebo group). Abdominal pain was also reported in 18% of patients. Most cases of diarrhea were mild-to-moderate, and approximately 4% of patients discontinued therapy due to this side effect.

How does Lynavoy’s mechanism differ from Ocaliva (obeticholic acid) or UDCA?

UDCA and Ocaliva (an FXR agonist) are disease-modifying therapies designed to reduce bile acid production and slow liver damage, measured by lowering alkaline phosphatase (ALP) levels. Lynavoy is a symptomatic therapy designed specifically to block the reabsorption of bile acids in the distal ileum, lowering systemic blood levels of bile acids to reduce cholestatic pruritus (itching).

Will commercial insurance plans require patients to try other drugs before covering Lynavoy?

Yes. Payer policies are expected to require a documented trial and failure of low-cost, off-label bile acid sequestrants (such as cholestyramine) for at least 4 weeks before approving Lynavoy. Additionally, payers will require verification of compensated liver function (ruling out decompensated cirrhosis).

---

Sources

• U.S. Food and Drug Administration. Novel Drug Approvals for 2026 (Lynavoy | linerixibat | Approved March 17, 2026). FDA Center for Drug Evaluation and Research. https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026
• GSK. GSK and Alfasigma Announce Licensing Agreement for Linerixibat, a First-in-Class Treatment for Cholestatic Pruritus in PBC. GSK Press Office, March 2026. https://www.gsk.com/en-gb/media/press-releases/gsk-and-alfasigma-announce-licensing-agreement-for-linerixibat/
• Alfasigma S.p.A. Alfasigma Completes Acquisition of Linerixibat Worldwide Licensing Rights from GSK. Alfasigma Corporate News, April 2026. https://www.alfasigma.com
• GSK. Lynavoy (linerixibat) Approved by the US FDA for Cholestatic Pruritus in Patients with Primary Biliary Cholangitis (PBC). GSK Press Office, 2026. https://www.gsk.com/en-gb/media/press-releases/lynavoy-linerixibat-approved-by-the-us-fda
• Phase 3 GLISTEN Trial Efficacy and Safety of Linerixibat for Cholestatic Pruritus in Primary Biliary Cholangitis. ClinicalTrials.gov Identifier: NCT04950127. Published in The Lancet Gastroenterology & Hepatology (2026).
• U.S. FDA. LYNAVOY (linerixibat) tablets Prescribing Information (Initial U.S. Approval: 2026). https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220295Orig1s000lbl.pdf
• American Association for the Study of Liver Diseases (AASLD). Practice Guidelines for the Diagnosis and Management of Primary Biliary Cholangitis. AASLD publications, 2025.